Selective Inhibition of<i>Escherichia coli</i>RNA and DNA Topoisomerase I by Hoechst 33258 Derived Mono- and Bisbenzimidazoles
作者:Nihar Ranjan、Sandra Story、Geraldine Fulcrand、Fenfei Leng、Muzammil Ahmad、Ada King、Souvik Sur、Weidong Wang、Yuk-Ching Tse-Dinh、Dev P. Arya
DOI:10.1021/acs.jmedchem.7b00191
日期:2017.6.22
Escherichia coli DNA topoisomerase I inhibition, binding to B-DNA duplex, and antibacterial activity has been evaluated. Bisbenzimidazoles with alkynyl side chains display excellent E. coli DNA topoisomerase I inhibition properties with IC50 values <5.0 μM. Several bisbenzimidazoles (3, 6, 7, 8) also inhibit RNA topoisomerase activity of E. coli DNA topoisomerase I. Bisbenzimidazoles inhibit bacterial growth
已经合成了一系列基于Hoechst 33258的单和双苯并咪唑类化合物,并评估了它们对大肠杆菌DNA拓扑异构酶I的抑制作用,与B-DNA双链体的结合以及抗菌活性。具有炔基侧链的双苯并咪唑类化合物具有出色的大肠杆菌DNA拓扑异构酶I抑制特性,IC 50值<5.0μM。几个bisbenzimidazoles(3,6,7,8)也抑制拓扑异构酶的RNA的活性的大肠杆菌DNA拓扑异构酶I.对于革兰氏阳性菌株,双苯并咪唑类抑制细菌生长的效果比单苯并咪唑类更好。革兰氏阳性菌(肠球菌和葡萄球菌,包括两个MRSA菌株0.3–8μg/ mL)的最低抑菌浓度(MIC)比大多数革兰氏阴性菌(铜绿假单胞菌,16–32μg)低/ mL,肺炎克雷伯菌> 32μg/ mL)。Bisbenzimidazoles具有稳定的B-DNA双链体(1.2−23.4°C),细胞毒性研究表明,类似的变化取决于侧链长度。建模研究表明,